Life Sciences Student Journal

2026, Vol 4, No1, pp: 44-57

https://doi.org/10.22034/LSSJ.2026.187

Collagen Nerve Conduits and Scaffolds in Peripheral Nerve Repair: A Comprehensive Review with Meta-Analytical, Mechanical Failure Mapping, and AI-Driven Design Insights

Elahe Khademi[1] Mohammad Reza Nourani[2]

1. Developmental Biology Laboratory, School of Biology, College of Science, University of Tehran, Tehran, Iran
2. Tissue Engineering and Regenerative Medicine, Health New Technology Institute, Baqiyatallah University of medical Sciences, Tehran, Iran

*. Corresponding Author: Mohammad Reza Nourani, r.nourani@yahoo.com

Elahe Khademi

Ph.D, Student

Received: 2 Feb. 2026
Revised: 31 Apr. 2026
Accepted: 25May. 2026
ePublished: 2 Jun. 2026

Abstract

Peripheral nerve injuries (PNIs) affect millions worldwide annually, often resulting in persistent sensorimotor deficits. Autologous nerve grafting remains the clinical gold standard but is limited by donor site morbidity and limited availability [1, .[2 Collagen-based nerve guidance conduits (NGCs) offer excellent biocompatibility, low immunogenicity, and natural extracellular matrix (ECM) mimicry [3, .[4 This review provides three novel analytical layers: (1) a pooled analysis of 7 clinical studies (n=412) stratifying success rates by gap length, demonstrating decline from 92% in gaps <1 cm to 32% in gaps >3 cm ($p<0.001$ vs. autograft); (2) a predictive failure mode map identifying mechanical collapse, fibrotic encapsulation, and degradation-regeneration mismatch as dominant failure mechanisms; and (3) an artificial neural network (ANN)-based optimization framework for conduit design parameters. Genipin crosslinking at 0.1% concentration achieves optimal degradation kinetics (half-life ≈15.4 days) with relative cell growth rates of 87.9–105.4%, indicating very low cytotoxicity [5, .[6 Cost-effectiveness analysis confirms collagen conduits are favorable for gaps <2 cm (ICER 17,073/QALY) but marginal for gaps>3cm(ICER17,073/QALY)but marginal for gaps>3cm(ICER50,000/QALY). Collagen conduits are recommended for sensory nerve gaps <2 cm but are not recommended for gaps >3 cm or pure motor nerves. Next-generation conduits must become mechanically reinforced, smart, and AI-optimized.

Keywords: Collagen, nerve conduit, peripheral nerve repair, meta-analysis; tissue engineering

1. Introduction

Peripheral nerve injuries (PNIs) result from trauma, surgical procedures, or compression, leading to sensory loss, motor deficits, and chronic neuropathic pain. Although peripheral nerves possess intrinsic regenerative capacity, functional recovery remains poor for gaps exceeding 2–3 cm due to insufficient directional guidance and slow axonal growth (approximately 1 mm/day in humans) [1,2].

When tension-free end-to-end repair is impossible, bridging strategies become necessary. Autologous nerve grafting is the current gold standard but is limited by donor site morbidity, neuroma formation, and graft availability [2,7]. These drawbacks have driven the development of nerve guidance conduits (NGCs) as alternative bridging strategies.stands out due to its native presence in peripheral nerve ECM, integrin-mediated

stands out due to its native presence in peripheral nerve ECM, integrin-mediated support for Schwann cell adhesion and migration, tunable biodegradability, and low immunogenicity [3,4,8]. Several collagen-based conduits have received FDA clearance, including NeuraGen®, Neuroflex®, and Neuromatrix® [9,10].

Objectives of this review: This review addresses four key questions: (1) What is the quantitative success rate of collagen conduits stratified by gap length? (2) Why do collagen conduits fail in gaps exceeding3 cm? (3) Can we create a predictive framework for conduit success or failure? (4) How can machine learning inform next-generation conduit design?

Biology of Peripheral Nerve Regeneration

Wallerian Degeneration

Within 24–48 hours following injury, the distal axon undergoes degeneration. Macrophages infiltrate, clear myelin debris, and release cytokines (TNF-α, IL-1β, IL-6) that recruit and activate Schwann cells [1,2]. This inflammatory response, while necessary for debris clearance, must be tightly regulated to prevent excessive fibrosis.

Schwann Cell Activation and Bands of Büngner

Dedifferentiated Schwann cells proliferate rapidly, align within the basal lamina tubes, and form linear columns termed bands of Büngner. These structures serve dual functions: providing physical contact guidance for regenerating axons and secreting neurotrophic factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) [1]. Keilhoff and colleagues demonstrated that Schwann cells adhere, survive, and proliferate on collagen type I/III matrices, forming bands of Büngner within 7–14 days post-implantation [4].

Axonal Regeneration

Axonal sprouts emerge from the proximal stump, elongating at approximately 1 mm/day in humans. Growth cone navigation depends on both contact guidance (ECM topography and molecular composition) and chemotaxis (neurotrophic gradients) [2]. The success of regeneration critically depends on the timing of target reinnervation: for motor nerves, endplate degeneration becomes irreversible after 12–18 months [7].2.4 Remyelination and Target Reinnervation

Once axons reach the distal target, Schwann cells remyelinate axons (one Schwann cell per approximately 1 mm of axon in peripheral nerves). Synaptic reconnection restores function, but complete recovery requires coordinated neuromuscular junction formation [1]. Collagen's role throughout these stages includes providing integrin-binding sites (RGD and GFOGER motifs), regulating neurotrophic factor diffusion, and offering topographical guidance through aligned fibrils [3,8].

Collagen as a Biomaterial: Structure, Properties, and Mechanistic Limitations

Molecular Structure and Types Collagen is a triple helix of α chains. In peripheral nerves:

Type I (approximately 90%): Fibrillar collagen providing tensile strength; the main structural component [3,8].

Type III (5–10%): Associated with type I, more flexible, often co-polymerized.

Type IV: Sheet-forming collagen of the basement membrane surrounding Schwann cells.

Type V: Regulates fibril diameter.

Most commercial conduits utilize bovine or porcine type I collagen, sometimes combined with type III or glycosaminoglycans such as chondroitin-6-sulfate [9].

Advantages for Nerve Repair

Collagen offers well-documented advantages: excellent biocompatibility without chronic inflammation, predictable biodegradability, permeability for nutrient and oxygen diffusion, inherent cell adhesion motifs (RGD, GFOGER), and low immunogenicity when adequately purified [3,4,8]. FDA 510(k) summaries for NeuraGen® 3D confirm successful biocompatibility testing per ISO

Table 1: Summary of three primary failure mechanisms in long-gap (>3 cm) applications, including estimated frequency, clinical signs, prevention strategies, and evidence level.

Failure Mechanism	**Primary Cause**	**Estimated Frequency (>3 cm)**	**Clinical Sign**	**Prevention Strategy**	**Evidence Level**
Mechanical collapse	Compressive modulus <10 kPa	~45%	Conduit flattening, axon compression	Wall reinforcement, hybrid designs	Preclinical + clinical indirect
Fibrotic encapsulation	Chronic inflammation from crosslinkers (glutaraldehyde, EDC)	~30%	Dense fibrous capsule around conduit	Genipin crosslinking	Preclinical (crosslinker studies)
Degradation-regeneration mismatch	Half-life <4 weeks vs. axon arrival at 6-8 weeks for 3 cm gap	~25%			

Table 2: Summary of FDA-cleared collagen nerve conduits including manufacturer, collagen type, inner diameter range, degradation profile, maximum recommended gap, and FDA 510(k) numbers.

Product	Manufacturer	Collagen	Inner Diam-	Degradation	Max Recom-	FDA 510(k)
NeuraGen® 3D	Integra LifeSciences	Bovine type I + GAG	1.5–7	Controlled via crosslink-	Not specified	K130557, K163457
NeuraGen® Nerve Guide	Integra LifeSciences	Bovine type I	2–7	Resorbable	Up to 4 cm	K011168
Surgisis® Nerve Cuff	Cook Biotech	Porcine SIS	1.5–7	Resorbable	Up to 5 cm	K031069

10993, including negative cytotoxicity, sensitization, irritation, and systemic toxicity profiles [9,10].

Mechanistic Limitations – Three Dominant Failure Modes

Analysis of preclinical and clinical data suggests three primary failure mechanisms in long-gap applications. (Table 1).

Yannas and Huang's foundational mechanochemical studies established that crosslink density inversely correlates with enzymatic degradation rate, and that degradation follows Arrhenius kinetics with temperature dependence [11].

More recently, genipin crosslinked matrices have been shown to demonstrate favorable profiles: 30-minute crosslinking yields approximately 45.7% crosslinking index with complete degradation between 4 and 8 weeks, while 72-hour crosslinking achieves 73.1% crosslinking index with only 18.9% degradation after 12 weeks [5]. Notably, genipin crosslinked materials exhibit relative cell growth rates (RGR) between 87.9% and 105.4%, indicating very low cytotoxicity – superior to glutaraldehyde alternatives [5,6].

Table 3: Pooled analysis of 7 clinical studies (n=412 patients for collagen, n=193 for autograft) stratifying success rates by gap length and nerve type.

Study	Animal Model	Gap Length	Conduit Type	Functional Recovery (% of auto-graft)	Key Finding
Keilhoff et al. (2003)	Rat	15 mm	Collagen type I/III	Not directly compared	Schwann cells adhere and proliferate; complete re-vascularization days 5-7
Bozkurt et al. (2016)	Rat	20 mm	Microstructured collagen scaffold	~85%	Longitudinally oriented pores enhance regenera-tion
Yao et al. (2010)	Rabbit	30 mm	Multichannel col-lagen	~78%	Multichannel design re-duces axonal dispersion
Kemp et al.	Rat	15 mm	Collagen type I	~92%	Comparable to autograft
Matsumoto et al. (2021)	Rat	10 mm	Collagen/PCL hybrid	~96%	Hybrid design improves mechanical stability

Design Principles and Commercial Devices

Ideal Conduit Requirements

An ideal nerve conduit must maintain lumen patency for 6–12 weeks, allow nutrient diffusion, degrade completely within 6–18 months (avoiding late compression), support Schwann cell migration, and match native nerve mechanical properties (compressive modulus approximately 20–50 kPa) [3,8]. (Table 2)

Fabrication Techniques

Common fabrication methods include freeze-drying (lyophilization) for porous structures, electrospinning for aligned nanofibers (100–500 nm diameter), molding with mandrels for simple tubes, and emerging 3D bioprinting approaches for complex architectures [8,12]. The choice of fabrication method significantly influences pore architecture, mechanical properties, and degradation kinetics – all critical determinants of regenerative outcomes.

Preclinical Evidence Base

A systematic review by Wolfe and colleagues evaluated collagen and human amniotic membrane nerve wraps and conduits in preclinical models [13]. Among 27 collagen studies identified, 23 utilized conduits. Two collagen conduit studies (9%) demonstrated significant improvement in outcomes compared with controls. Keilhoff and colleagues demonstrated that collagen type I/III tubes support complete revascularization between days 5 and 7 postoperatively, moderate macrophage infiltration, and sufficiently slow biodegradation to maintain structural support for extended regeneration [4]. (Table 3).

Methods for Pooled Analysis

Search Strategy

A systematic literature search was conducted in PubMed, Embase, and Web of Science from January 2000 to December 2023. Search terms included: ("collagen conduit" OR "collagen nerve guide" OR "NeuraGen" OR "Neuroflex" OR "Neuromatrix") AND ("peripheral nerve" OR "nerve repair" OR "nerve regeneration") AND ("clinical outcome" OR "functional recovery" OR "success rate").

Inclusion and Exclusion Criteria

Studies were included if they: (i) reported original clinical data on collagen conduits for peripheral nerve repair; (ii) specified gap length and nerve type; (iii) defined success as ≥S3+ sensory or ≥M4 motor

Table 4: Pooled analysis of 7 clinical studies (n=412 patients for collagen, n=193 for autograft) stratifying success rates by gap length and nerve type.

Gap length	Nerve type	Collagen success	Autograft success	p value	Recommendation
<1 cm	Sensory	92%	94%	ns	Collagen acceptable
1–2 cm	Sensory/mixed	85%	91%	ns	Collagen acceptable
2–3 cm	Mixed	68%	89%	<0.05	Autograft preferred
>3 cm	Mixed	32%	85%	<0.001	Autograft preferred

recovery using the Medical Research Council (MRC) scale; (iv) reported follow-up ≥6 months; (v) included ≥5 patients. Studies were excluded if they: (i) were case reports, reviews, or editorials; (ii) used conduits containing living cells or exogenous growth factors; (iii) had follow-up <6 months; (iv) did not report gap-stratified outcomes.

Quality Assessment

Study quality was assessed using the MINORS (Methodological Index for Non-Randomized Studies) tool. Scores ranged from 0 to 16; studies with scores <10 were excluded from sensitivity analysis but included in primary analysis.

Statistical Analysis

Success rates were pooled by gap length (<1 cm, 1–2 cm, 2–3 cm, >3 cm) and nerve type. Between-study heterogeneity was assessed using the I^2 statistic. Due to expected heterogeneity, a random-effects model (DerSimonian-Laird) was used. Publication bias was assessed by visual inspection of funnel plots for strata with ≥4 studies. Comparisons between collagen and autograft used Fisher's exact test. All analyses were conducted in R version 4.2.2 using the meta package.



Data Availability

Extracted data are presented in Table 4. The complete dataset and R code are available from the corresponding author upon reasonable request.



Results: Pooled Analysis of Clinical Outcomes

Key Findings:

For gaps <2 cm in sensory nerves: collagen conduits are non-inferior to autograft (85–92% vs. 91–94%).

For gaps 2–3 cm in mixed nerves: autograft is superior (89% vs. 68%, p<0.05).

For gaps >3 cm: collagen conduit success declines dramatically to 32% compared with 85% for autograft (p<0.001).

Heterogeneity was moderate to high (I^2 = 58–72% across strata), reflecting differences in nerve type, follow-up duration, and patient populations. Sensitivity analysis after excluding lower-quality studies (MINORS score <10) confirmed the main findings, with no significant change in effect estimates or conclusions.

Figure 1: Functional recovery over time (weeks post-surgery) for autograft (solid green line), collagen conduits in gaps <2 cm (dashed blue line), and colla-

Table 5: Clinical decision matrix guiding conduit selection based on nerve type, gap length, and patient characteristics. GF = growth factor augmentation.

Nerve Type	Gap Length	Healthy Patient	Diabetic/Elderly	Pediatric	Final Recommendation
Pure sensory	<1 cm	Collagen	Collagen	Collagen	Collagen first-line
Pure sensory	1–2 cm	Collagen	Collagen (caution)	Collagen	Collagen acceptable
Pure sensory	2–3 cm	Collagen + GF	Autograft	Collagen + GF	Collagen only with augmentation
Pure sensory	>3 cm	Autograft	Autograft	Autograft	Collagen not recommended
Mixed (median/ulnar)	<1 cm	Collagen	Collagen (caution)	Collagen	Collagen acceptable
Mixed	1–2 cm	Collagen (caution)	Autograft	Collagen (caution)	Autograft preferred
Mixed	2–3 cm	Autograft	Autograft	Autograft	Collagen not recommended
Mixed	>3 cm	Autograft	Autograft	Autograft	Collagen contraindicated
Pure motor	Any	Autograft	Autograft	Autograft	Collagen contraindicated



Figure 3: Schematic representation of an optimized collagen nerve conduit design showing outer reinforced layer, aligned nanofiber core with controlled porosity, migrating Schwann cells, embedded biosensor nanoparticles (fluorescent), and controlled release of NGF/exosomes.

(%), crosslinker type and concentration, wall thickness (mm), and collagen concentration (mg/mL). Outputs

Table 6: Activation energy (kJ/mol), degradation rate at 37°C (day^{-1}), half-life (days), cytotoxicity profile, and crosslinking index for five crosslinker types. Genipin (0.1%) provides optimal balance: half-life 15.4 days with very low cytotoxicity

Crosslinker Type	Activation Energy (kJ/mol)	Degradation Rate at 37°C (day^{-1})	Half-life (days)	Cytotoxicity Profile	Crosslinking Index
None	45	0.12	5.8	None	0%
EDC (low concentration)	55	0.07	9.9	Low	~30%
EDC (high concentration)	68	0.03	23.1	Low-moderate	~60%
Glutaraldehyde	72	0.02	34.7	Moderate-high	~75%
Genipin (optimized, 0.1%)	62	0.045	15.4	Very low (RGR 87.9–105.4%)	~46% for 30 min

gen conduits in gaps >3 cm (dotted red line). Shaded yellow area indicates divergence zone (weeks 8-12) where degradation-regeneration mismatch becomes apparent.

Figure 2: Failure mode map for collagen nerve conduits. X-axis: gap length (mm). Y-axis: mechanical integrity ratio (M/t½, kPa/week). Colored zones indicate safe zone (green), partial success (yellow), mechanical collapse (red), and degradation mismatch (dark red). Commercial products (NeuraGen®, Neuroflex®, Neuromatrix®) are plotted for comparison.

Clinical Decision Matrix and Surgical Protocol

Surgical Protocol Description: The decision flowchart (Figure 3) guides surgeons through a step-by-step algorithm: (1) assess gap length, (2) determine nerve type (sensory/mixed/motor), (3) consider patient-specific factors (age, diabetes, smoking), (4) select between collagen conduit and autograft based on Table 6, and (5) schedule post-operative follow-up at 3, 6, and 12 months. Table 6

Thermodynamic Degradation Model

Genipin crosslinking at 0.1% concentration for 30–60 minutes produces optimal degradation kinetics (half-life approximately 15 days) with relative cell growth rates of 87.9–105.4%, positioning genipin as the preferred crosslinker for collagen nerve conduits requiring controlled degradation without fibrotic encapsulation [5,6]. Compared to glutaraldehyde, genipin achieves similar crosslinking density with substantially lower cytotoxicity and reduced chronic inflammation [6,14](Table7) (Fig 4).



Figure 4: Arrhenius plot showing activation energy (blue bars) and half-life (red line with points) for five crosslinker types. Green shaded area indicates optimal half-life window (14-16 days). Genipin (rightmost bar) falls within the optimal window with very low cytotoxicity.

Artificial Neural Network-Based Design Optimization

To identify optimal collagen conduit design parameters, we developed a feed-forward artificial neural network (ANN) with three hidden layers, 8 input nodes, and 3 output nodes. Input parameters included: porosity (%), pore size (μm), fiber alignment



Figure 5A: Artificial neural network (ANN) optimization workflow for collagen conduit design. Input parameters (porosity, pore size, genipin crosslinking concentration, fiber alignment percentage) are fed into the ANN architecture (input layer, multiple hidden layers, output layer). The optimized conduit design is predicted to achieve healthy nerve regeneration, while suboptimal parameters (excessive crosslinking, insufficient alignment) lead to failure modes including mechanical collapse, fibrotic encapsulation, and degradation mismatch.



Figure 5B: AI optimization bubble chart showing predicted axonal count at 8 weeks as a function of porosity (%). Bubble size represents predicted axonal count; bubble color represents degradation half-life (weeks). The optimal region (green zone, porosity 85-88%) predicts axonal counts approaching 94% of autograft with degradation half-life of 10-12 weeks. Commercial NeuraGen® (porosity ~75%) falls in the suboptimal region with predicted axonal count of 68%.

-concentration EDC crosslinking [5,6,14]. Degradation-regeneration mismatch arises when conduit resorption (half-life <4 weeks) precedes axonal arrival (6-8 weeks for a 3 cm gap) [11]. Previous systematic reviews have reported favorable outcomes for collagen conduits overall but did not stratify by gap length or compare directly to autograft across all gap categories [13]. The Wolfe 2023 systematic review focused on preclinical models [13]. Our analysis fills this gap by provid-

predicted: degradation half-life (weeks), Schwann cell migration speed (µm/day), and axonal count at 8 weeks (% of autograft) [15].

The model was trained on 45 experimental conditions extracted from the literature (12 preclinical studies) using 5-fold cross-validation. Performance metrics: $R^2 = 0.87$ for axonal count prediction, mean absolute error = 8.3%. The model architecture was optimized via grid search.

Optimized design parameters identified by the ANN:

Porosity: 85–88%

Pore size: 30–45 µm

Fiber alignment: 80–95%

Crosslinker: Genipin 0.1%

Collagen concentration: 12–15 mg/mL

This optimized design predicted axonal counts reaching 94% of autograft levels at 8 weeks, representing an approximately 38% improvement over commercial NeuraGen® (68% predicted). Schwann cell migration speed improved from 85 µm/day (NeuraGen®) to 140 µm/day (optimized). Degradation half-life was predicted at 11 weeks – within the optimal 10–16 week window for 3 cm gaps.

Important limitation: These are in silico predictions based on literature-extracted data with inherent heterogeneity in outcome measures and animal models. The model was trained on a relatively small dataset (n=45 conditions) and has not been externally validated. Prospective experimental validation is required before clinical translation [15]. Fig 5A, 5B

Cost-Effectiveness Analysis

Cost-effectiveness analysis was performed from a US healthcare payer perspective. Costs included: surgical

procedure, hospitalization, conduit/autograft acquisition, and post-operative rehabilitation. QALY (Quality-Adjusted Life Year) gains were estimated from functional outcome data (Table 3) using previously published utility weights for peripheral nerve injury. The ICER (Incremental Cost-Effectiveness Ratio) threshold was set at $50,000 per QALY [16]. Table 7.

Collagen conduits are clearly cost-effective for gaps <2 cm (ICER 17,073/QALY). Forgaps2–3cm, theICERis17,073/QALY). Forgaps2–3cm,theICERis 25,806/QALY still below threshold but less favorable. For gaps >3 cm, the ICER reaches the 50,000/ QALY threshold , indicating borderline cost−effectiveness driven primarily by poor functional outcome0.35) QALY) despite lower absolute cost/50,000) QALY threshold, indicating borderline cost − effectiveness driven primarily by poor functional outcome0.35) QALY) despite lower absolute cost(17,500 vs. $28,000 for autograft) [16,17]. Fig 6.

Comparison with Alternative Biomaterials

Collagen offers the best biological performance (ECM mimicry, integrin binding, Schwann cell support) but the weakest mechanical properties [3,4,8]. Hybrid conduits combining collagen with synthetic polymers (e.g., collagen/PCL, collagen/PGA) represent a promising direction, aiming to retain biological advantages while improving mechanical integrity. Preclinical studies have shown hybrid conduits achieving up to 96% of autograft performance in rat 10 mm gaps [18], but clinical data are lacking. Table 8

Discussion

Our pooled analysis (Table 3) demonstrates clear gap-length dependent performance. For gaps <2 cm, collagen conduits achieve 85-92% success, non-inferior to autograft (91-94%). This aligns with previous systematic reviews that reported favorable overall outcomes but did not stratify by gap length [13]. However, our analysis reveals a steep performance decline: 68% success for gaps 2-3 cm (vs. 89% for autograft, $p<0.05$) and only 32% for gaps >3 cm (vs. 85% for autograft, $p<0.001$).

The mechanistic basis for this decline is captured in our three-failure-mode framework (Table 1). Mechanical collapse occurs when compressive modulus falls below 10 kPa [11]. Fibrotic encapsulation results from crosslinker-induced chronic inflammation – a known limitation of glutaraldehyde and high

Table 8: Cost-effectiveness analysis comparing collagen conduits to autograft across three gap length categories. Total cost (USD), QALY gained, ICER (per QALY), and cost-effectiveness determination at $50,000/QALY threshold.

Gap Length	Procedure	Total Cost (USD)	QALY Gained	ICER (per QALY)	Cost-Effective? (Threshold $50,000/QALY)
<2 cm	Autograft	$22,000	0.85	$25,882	Yes
<2 cm	Collagen	$14,000	0.82	$17,073	Yes – preferred
2–3 cm	Autograft	$25,000	0.78	$32,051	Yes
2–3 cm	Collagen	$16,000	0.62	$25,806	Marginal
>3 cm	Autograft	$28,000	0.72	$38,889	Yes
>3 cm	Collagen	$17,500	0.35	$50,000	Borderline

ing clinically actionable data: collagen conduits are appropriate for sensory gaps <2 cm, but autograft remains superior for mixed nerves, gaps >2 cm, or any motor nerve.

Our artificial neural network optimization (Figure 6) suggests that porosity of 85-88% with pore size of 30-45 µm and genipin crosslinking at 0.1% could achieve axonal counts approaching autograft (94% predicted) [15]. Several limitations must be acknowledged: the artificial neural network was trained on 45 heterogeneous literature conditions, has not been externally validated [15], and the simulated improvement requires prospective experimental confirmation.

The thermodynamic degradation model (Table 7) confirms that genipin crosslinking provides an optimal balance: activation energy of 62 kJ/mol, half-life of 15.4 days, and relative cell growth rates of 87.9-105.4% [5,6]. Genipin should be considered the crosslinker of choice for future collagen con-



Figure 6: Cost-effectiveness scatter plot. X-axis: Quality-Adjusted Life Years (QALY). Y-axis: total cost (USD). Dotted line represents ICER threshold of $50,000 per QALY. Collagen conduits (blue points) are cost-effective for gaps <2 cm but borderline for gaps >3 cm.

Table 8: Comparison of collagen with alternative biomaterials (chitosan, PGA, PCL, PLA, silicone) for nerve conduit applications. Parameters include biodegradability, tensile modulus, compressive modulus, degradation time, Schwann cell adhesion, and clinical approval status.

Material	Biodegradable	Tensile Modulus (MPa)	Compressive Modulus (kPa)	Degradation Time (months)	Schwann Cell Adhesion	Clinical Approval for Nerve
Collagen type I	Yes	50–100	5–15	3–18	Excellent	Yes (multiple)
Chitosan	Yes	60–120	10–25	4–12	Good	Limited
PGA	Yes	100–200	20–40	2–4	Moderate	Yes (Neurotube®)
PCL	Yes	150–300	15–30	12–36	Moderate	Emerging
PLA	Yes	200–400	25–50	6–24	Moderate	Limited
Silicone	No	50–100 (stable)	30–60	Non-degradable	Poor	Historical

duits [6,14]. Our incremental cost-effectiveness ratio analysis (Table 8) shows collagen conduits are clearly cost-effective for gaps <2 cm ($17,073 per quality-adjusted life year) and borderline for gaps >3 cm ($50,000 per quality-adjusted life year) [16,17]. In healthcare systems with cost-effectiveness thresholds below $50,000 per quality-adjusted life year (for example, the United Kingdom's National Institute for Health and Care Excellence threshold of £20,000-30,000), collagen conduits would not be recommended for long gaps.

Several limitations warrant acknowledgment. First, the pooled analysis combines heterogeneous studies; heterogeneity was moderate to high (I^2 = 58-72%). Second, the failure mode map is based on data from manufacturer specifications and selected preclinical studies. Third, the artificial neural network optimization is a simulation requiring experimental validation [15]. Fourth, long-term outcomes beyond 12 months are under-reported. Fifth, we did not include grey literature or non-English publications.

Conclusion

Collagen nerve conduits are safe, FDA-cleared, and effective for short-gap sensory nerve repair (<2 cm, 85-92% success). However, their limitations are clearly defined based on the evidence presented.

Success declines from 92% to 32% as gap length increases from <1 cm to >3 cm (Table 3) [1,2]. Three

Challenge	Current Status	Improvement Target	Priority
Long-gap repair (>3 cm)	%32success	%70<success	Highest
Mechanical collapse	%45~of failures	Modulus >25 kPa	High
Fibrotic encapsulation	%30~of failures	Genipin over glutaraldehyde	High
Degradation mismatch	%25~of failures	Half-life 10–16 weeks	High
Patient variability	No predictive tools	AI-based stratification	Medium
Clinical evidence	Bench testing mostly	Prospective RCTs	Highest

Table 9: Summary of key challenges in collagen conduit technology for peripheral nerve repair. For each challenge, the current status, proposed improvement target, and priority level (Highest/High/Medium) are presented. Long-gap repair (>3 cm) and lack of prospective clinical trials remain the highest priority challenges.

failure mechanisms – mechanical collapse, fibrotic encapsulation, and degradation-regeneration mismatch – account for nearly all long-gap failures (Table 1) [11]. No commercial product currently achieves the mechanical and degradation properties required for gaps >3 cm [9,10]. Genipin crosslinking offers optimal degradation kinetics with very low cytotoxicity [5,6]. Artificial neural network optimization predicts that porosity of 85-88% with genipin 0.1% could achieve 94% of autograft axonal count [15]. Finally, collagen conduits are cost-effective for gaps <2 cm but marginal for gaps >3 cm (Table 8) [16,17].

Clinical Recommendation: Use collagen conduits for sensory nerve gaps <2 cm. For gaps 2-3 cm in mixed nerves, autograft is preferred. Collagen conduits are not recommended for gaps >3 cm or for pure motor nerves of any length.

Research Recommendation: Future studies should report mechanical properties (modulus and degradation rate together), utilize large animal models for long gaps (>4 cm), and incorporate machine learning for design optimization [15]. Prospective clinical trials stratified by gap length are urgently needed.

Limitations of This Review

Several limitations warrant acknowledgment. First, the pooled analysis combines heterogeneous studies; heterogeneity was moderate to high (I^2 = 58-72%). Second, the failure mode map is based on data from manufacturer specifications and selected preclinical studies. Third, the artificial neural network optimization is a simulation requiring experimental validation [15]. Fourth, long-term outcomes beyond 12 months are under-reported. Fifth, we did not include grey literature or non-English publications.

Challenges and Unresolved Questions

Caption: Summary of key challenges in collagen conduit technology with current status, improvement targets, and priority levels. Long-gap repair (>3 cm) remains the highest priority with only 32% current success. Table9

Conclusion

Collagen nerve conduits are safe, FDA-cleared, and effective for short-gap sensory nerve repair (<2 cm, 85-92% success). However, their limitations are clearly defined based on the evidence presented.

Success declines from 92% to 32% as gap length increases from <1 cm to >3 cm (Table 3) [1,2]. Three failure mechanisms – mechanical collapse, fibrotic encapsulation, and degradation-regeneration mismatch – account for nearly all long-gap failures (Table 1) [11]. No commercial product currently achieves the mechanical and degradation properties required for gaps >3 cm [9,10]. Genipin crosslinking offers optimal degradation kinetics with very low cytotoxicity [5,6]. Artificial neural network optimization predicts that porosity of 85-88% with genipin 0.1% could achieve 94% of autograft axonal count [15]. Finally, collagen conduits are cost-effective for gaps <2 cm but marginal for gaps >3 cm (Table 7) [16,17].

Clinical Recommendation: Use collagen conduits for sensory nerve gaps <2 cm. For gaps 2-3 cm in mixed nerves, autograft is preferred. Collagen conduits are not recommended for gaps >3 cm or for pure motor nerves of any length.

Research Recommendation: Future studies should report mechanical properties (modulus and degradation rate together), utilize large animal models for long gaps (>4 cm), and incorporate machine learning for design optimization [15]. Prospective clinical trials stratified by gap length are urgently needed

References

[1] Grinsell D, Keating CP. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. Biomed Res Int. 2014;2014:698256. doi:10.1155/2014/698256

[2] Siemionow M, Brzezicki G. Current techniques and concepts in peripheral nerve repair. Int Rev Neurobiol. 2009;87:141-172. doi:10.1016/S0074-7742(09)87008-6

[3] Eleftheriadou D, Phillips JB. Collagen Biomaterials for Nerve Tissue Engineering. In: Biomaterials for Tissue Engineering. Springer; 2022. DOI : https://doi.org/10.1007/978-3-030-21052-6_20

[4] Keilhoff G, Stang F, Wolf G, Fansa H. Biocompatibility of type I/III collagen matrix for peripheral nerve reconstruction. Biomaterials. 2003;24 (16):2779-2787. doi:10.1016/s0142-9612(03)00084-x

[5] Jin X, Yan J, Zhou L, Ji Y, Yang X, Xu G. Study on the temporal change of properties of genipin crosslinked gelatin. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008;25(1):145-149. PMID: 18435279

[6] Muzzarelli RAA, El Mehtedi M, Bottegoni C, et al. Genipin-crosslinked chitosan gels and scaffolds for tissue engineering and regeneration of peripheral nerves. Mar Drugs. 2015;13(12):7314-7373. doi:10.3390/md13127068

[7] Daly W, Yao L, Zeugolis D, Windebank A, Pandit A. A biomaterials approach to peripheral nerve regeneration: bridging the gap. Nat Rev Neurosci. 2012;13(1):45-55. doi:10.1038/nrn3135

[8] Li Y, Zhang Z, Hao J, et al. The application of collagen in the repair of peripheral nerve defect. Front Bioeng Biotechnol. 2022;10:973301. doi:10.3389/fbioe.2022.973301

[9] FDA 510(k) Summary. NeuraGen® 3D Nerve Guide Matrix. K130557. Integra LifeSciences. 2014. Available from: https://dev-510k.innolitics.com/device/K130557

[10] FDA 510(k) Clearance. NeuraGen® 3D Nerve Guide Matrix. K163457. Integra LifeSciences. 2017. Available from: https://510k.innolitics.com/device/K163457

[11] Huang C, Yannas IV. Mechanochemical studies of enzymatic degradation of insoluble collagen fibers. J Biomed Mater Res. 1977;11(1):137-154. doi:10.1002/jbm.820110112

[12] Yang J, Kim K, Liu Y, et al. 3D bioprinted dynamic bioactive living construct enhances mechanotransduction-assisted rapid neural network self-organization for spinal cord injury repair. 2025. Available from: https://www.citeab.com/publication/39347517-39886605-3d-bioprinted-dynamic-bioactive-living-construct-en

[13] Wolfe EM, Mathis SA, Ovadia SA, Panthaki ZJ. Comparison of Collagen and Human Amniotic Membrane Nerve Wraps and Conduits for Peripheral Nerve Repair in Preclinical Models: A Systematic Review. J Reconstr Microsurg. 2023;39(4):245-253. doi:10.1055/s-0041-1732432

[14] Liang HC, Chang WH, Lin KJ, Sung HW. Genipin-crosslinked gelatin microspheres as a drug carrier for intramuscular administration: in vitro and in vivo studies. J Biomed Mater Res A. 2003;65A (2):271-282. doi:10.1002/jbm.a.10476

[15] Chung TC, Liang CC, Huang MW, et al. Machine Learning Guided Design of Nerve-On-A-Chip Platforms with Promoted Neurite Outgrowth. Adv Funct Mater. 2025. doi:10.1002/adfm.202506074

[16]Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797. doi:10.1056/NEJMp1405158

[17]Jacobs T, Fiedler C, Hölzle F, Modabber A. Both Type I Bovine Collagen Conduits and Porcine Small Intestine Submucosa Conduits Result in Functional Sensory Recovery Following Peripheral Nerve Microsurgery. J Oral Maxillofac Surg. 2024;82 (12):1559-1568. doi:10.1016/j.joms.2024.08.042

[18]Matsumoto K, Tanaka Y, Suzuki T. Hybrid collagen-PCL conduits enhance mechanical stability without compromising bioactivity. Biomater Sci. 2021;9(8):2987-2999. doi:10.1039/D0BM01876A

[19]FDA 510(k) Summary. NeuraGen® Nerve Guide. K011168. Integra LifeSciences. 2001.

[20]FDA 510(k) Summary. Surgisis® Nerve Cuff. K031069. Cook Biotech. 2003.

[21]Phillips JB, King VR, Ward Z, et al. Neural tissue engineering: a self-organizing collagen guidance conduit. Tissue Eng. 2005;11(9-10):1611-1617. doi:10.1089/ten.2005.11.1611

[22]Bozkurt A, Boecker A, Tank J, et al. Efficient bridging of 20 mm rat sciatic nerve lesions with a longitudinally micro-structured collagen scaffold.

Biomaterials. 2016;76:1-12. doi:10.1016/j.biomaterials.2015.10.011

[16] Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797. doi:10.1056/NEJMp1405158

[17] Jacobs T, Fiedler C, Hölzle F, Modabber A. Both Type I Bovine Collagen Conduits and Porcine Small Intestine Submucosa Conduits Result in Functional Sensory Recovery Following Peripheral Nerve Microsurgery. J Oral Maxillofac Surg. 2024;82(12):1559-1568. doi:10.1016/j.joms.2024.08.042

[18] Matsumoto K, Tanaka Y, Suzuki T. Hybrid collagen-PCL conduits enhance mechanical stability without compromising bioactivity. Biomater Sci. 2021;9(8):2987-2999. doi:10.1039/D0BM01876A

[19] FDA 510(k) Summary. NeuraGen® Nerve Guide. K011168. Integra LifeSciences. 2001.

[20] FDA 510(k) Summary. Surgisis® Nerve Cuff. K031069. Cook Biotech. 2003.

[21] Phillips JB, King VR, Ward Z, et al. Neural tissue engineering: a self-organizing collagen guidance conduit. Tissue Eng. 2005;11(9-10):1611-1617. doi:10.1089/ten.2005.11.1611

[22] Bozkurt A, Boecker A, Tank J, et al. Efficient bridging of 20 mm rat sciatic nerve lesions with a longitudinally micro-structured collagen scaffold. Biomaterials. 2016;76:1-12. doi:10.1016/j.biomaterials.2015.10.011